)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Zhangzhou Pientzehuang Pharmaceutical
Zhangzhou Pientzehuang Pharmaceutical (600436) investor relations material
Zhangzhou Pientzehuang Pharmaceutical Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary30 Oct, 2026
Executive summary
Q3 revenue fell 13.91% YoY to RMB 1,776,652,151.62; net profit attributable to shareholders declined 71.67% to RMB 194,666,741.82.
9M revenue decreased 14.68% YoY to RMB 6,349,495,773.18 and attributable net profit fell 39.53% to RMB 1,287,640,802.17.
Management attributed lower earnings to reduced pharmaceutical-industry profits and lower investment income at a subsidiary; 9M operating cash flow rose 376.05% to RMB 2,317,134,900.58.
Financial highlights
Q3 total profit was RMB 164,842,808.01, down 78.85% YoY; 9M total profit was RMB 1,453,452,092.53, down 41.51%.
Adjusted for non-recurring items, attributable net profit was RMB 250,890,181.94 in Q3, down 42.69%, and RMB 1,305,476,785.23 for 9M, down 30.95%.
9M basic and diluted EPS were both RMB 2.13, down 39.66%; Q3 EPS was RMB 0.32, down 71.93%.
9M operating revenue declined while operating costs fell to RMB 4,921,805,070.77 from RMB 5,323,980,740.23 YoY.
Segment performance
Pharmaceutical-industry profits declined, contributing to lower reported and adjusted earnings; no segment-level revenue breakdown is included in the reported figures.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Zhangzhou Pientzehuang Pharmaceutical
- 2024 revenue up 7.25% and net profit up 6.42%, with 60.19% payout ratio.600436
H2 2024 - Revenue and profit fell sharply year-over-year, but cash flow and online sales grew strongly.600436H1 2026
- Revenue and profit fell significantly, but cash dividends remained robust.600436H2 2025
- Revenue and profit declined sharply year-over-year, but operating cash flow improved.600436Q1 2026
- Revenue and profit dropped over 25% year-over-year amid weaker sales and margin pressure.600436Q3 2025
- Net profit fell 16.22% year-over-year, with a 58.56% interim dividend payout.600436H1 2025
- Double-digit revenue and profit growth offset by a significant drop in operating cash flow.600436Q3 2024
- H1 2024 revenue up 12% and net profit up 11.7%, led by pharmaceuticals and cosmetics.600436H1 2024
- Net profit up 2.59% year-over-year in Q1 2025, with strong cash flow growth.600436Q1 2025
Next Zhangzhou Pientzehuang Pharmaceutical earnings date
H2 202630 Apr, 2027
Zhangzhou Pientzehuang Pharmaceutical
Next Zhangzhou Pientzehuang Pharmaceutical earnings date
H2 202630 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. is a China-based pharmaceutical company engaged in the production and sale of traditional Chinese medicine (TCM) and healthcare products. The company is known for its development of products based on TCM formulations, which are used to address various health conditions and promote general well-being. Its offerings include prescription medicines, over-the-counter drugs, and health supplements, catering to both domestic and international markets. The company is headquartered in Zhangzhou, China, and its shares are listed on the Shanghai Stock Exchange.